Literature DB >> 28059711

T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.

C Thaler1, T D Faizy2, J Sedlacik2, B Holst2, K Stürner3,4, C Heesen3,4, J-P Stellmann3,4, J Fiehler2, S Siemonsen2,4.   

Abstract

BACKGROUND AND
PURPOSE: Quantitative MR imaging parameters help to evaluate disease progression in multiple sclerosis and increase correlation with clinical disability. We therefore hypothesized that T1 values might be a marker for ongoing tissue damage or even remyelination and may help increase clinical correlation.
MATERIALS AND METHODS: MR imaging was performed in 17 patients with relapsing-remitting MS at baseline and after 12 months of starting immunotherapy with dimethyl fumarate. On baseline images, lesion segmentation was performed for normal-appearing white matter, T2 hyperintense (FLAIR lesions), T1 hypointense (black holes), and contrast-enhancing lesions, and T1 relaxation times were obtained at baseline and after 12 months. Changes in clinical status were assessed by using the Expanded Disability Status Scale and Symbol Digit Modalities Test at both dates (Expanded Disability Status Scale-difference/Symbol Digit Modalities Test-diff).
RESULTS: The highest T1 relaxation time at baseline was measured in black holes (1460.2 ± 209.46 ms) followed by FLAIR lesions (1400.38 ± 189.1 ms), pure FLAIR lesions (1327.5 ± 210.04 ms), contrast-enhancing lesions (1205.59 ± 199.95 ms), and normal-appearing white matter (851.34 ± 30.61 ms). After 12 months, T1 values had decreased significantly in black holes (1369.4 ± 267.81 ms), contrast-enhancing lesions (1079.57 ± 183.36 ms) (both P < .001), and normal-appearing white matter (841.98 ± 36.1 ms, P = .006). With the Jonckheere-Terpstra Test, better clinical scores were associated with decreasing T1 relaxation times in black holes (P < .05).
CONCLUSIONS: T1 relaxation time is a useful quantitative MR imaging technique, which helps detect changes in MS lesions with time. We assume that these changes are associated with the degree of myelination within the lesions themselves and are pronounced in black holes. Additionally, decreasing T1 values in black holes were associated with clinical improvement.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2016        PMID: 28059711      PMCID: PMC7963813          DOI: 10.3174/ajnr.A5004

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  38 in total

Review 1.  Advances in imaging to support the development of novel therapies for multiple sclerosis.

Authors:  D H Miller; D R Altmann; D T Chard
Journal:  Clin Pharmacol Ther       Date:  2012-03-07       Impact factor: 6.875

2.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions.

Authors:  C J De Groot; E Bergers; W Kamphorst; R Ravid; C H Polman; F Barkhof; P van der Valk
Journal:  Brain       Date:  2001-08       Impact factor: 13.501

3.  Remyelination is extensive in a subset of multiple sclerosis patients.

Authors:  Peter Patrikios; Christine Stadelmann; Alexandra Kutzelnigg; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Wolfgang Brück; Claudia Lucchinetti; Hans Lassmann
Journal:  Brain       Date:  2006-08-18       Impact factor: 13.501

4.  Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis.

Authors:  M Rovaris; M Filippi; L Minicucci; G Iannucci; G Santuccio; F Possa; G Comi
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

5.  Multiple sclerosis: remyelination in acute lesions.

Authors:  C S Raine; E Wu
Journal:  J Neuropathol Exp Neurol       Date:  1993-05       Impact factor: 3.685

6.  Tissue-specific imaging is a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage.

Authors:  M Riva; V N Ikonomidou; J J Ostuni; P van Gelderen; S Auh; J M Ohayon; F Tovar-Moll; N D Richert; J H Duyn; F Bagnato
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-30       Impact factor: 3.825

7.  MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field.

Authors:  José P Marques; Tobias Kober; Gunnar Krueger; Wietske van der Zwaag; Pierre-François Van de Moortele; Rolf Gruetter
Journal:  Neuroimage       Date:  2009-10-09       Impact factor: 6.556

8.  T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.

Authors:  Christian Thaler; Tobias Faizy; Jan Sedlacik; Brigitte Holst; Jan-Patrick Stellmann; Kim Lea Young; Christoph Heesen; Jens Fiehler; Susanne Siemonsen
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

9.  Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain.

Authors:  Klaus Schmierer; Francesco Scaravilli; Daniel R Altmann; Gareth J Barker; David H Miller
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

10.  MP2RAGE provides new clinically-compatible correlates of mild cognitive deficits in relapsing-remitting multiple sclerosis.

Authors:  Samanta Simioni; Fabio Amarù; Guillaume Bonnier; Tobias Kober; David Rotzinger; Renaud Du Pasquier; Myriam Schluep; Reto Meuli; Andrea Sbarbati; Jean-Philippe Thiran; Gunnar Krueger; Cristina Granziera
Journal:  J Neurol       Date:  2014-06-10       Impact factor: 4.849

View more
  9 in total

1.  A new frontier for amyloid PET imaging: multiple sclerosis.

Authors:  Silvia Morbelli; Matteo Bauckneht; Selene Capitanio; Matteo Pardini; Luca Roccatagliata; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-15       Impact factor: 9.236

2.  Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients.

Authors:  Natalia Nowaczyk; Alicja Kalinowska-Łyszczarz; Włodzimierz Paprzycki; Sławomir Michalak; Radosław Kaźmierski; Mikołaj A Pawlak
Journal:  Neurol Neurochir Pol       Date:  2019-02-11       Impact factor: 1.621

3.  The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.

Authors:  Christian Thaler; Tobias D Faizy; Jan Sedlacik; Maxim Bester; Jan-Patrick Stellmann; Christoph Heesen; Jens Fiehler; Susanne Siemonsen
Journal:  J Neurol       Date:  2017-11-20       Impact factor: 4.849

4.  Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.

Authors:  Cristina Granziera; Jens Wuerfel; Frederik Barkhof; Massimiliano Calabrese; Nicola De Stefano; Christian Enzinger; Nikos Evangelou; Massimo Filippi; Jeroen J G Geurts; Daniel S Reich; Maria A Rocca; Stefan Ropele; Àlex Rovira; Pascal Sati; Ahmed T Toosy; Hugo Vrenken; Claudia A M Gandini Wheeler-Kingshott; Ludwig Kappos
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

5.  Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

Authors:  Fredrika Koskimäki; Jacqueline Bernard; Jeong Yong; Nancy Arndt; Timothy Carroll; Seon-Kyu Lee; Anthony T Reder; Adil Javed
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

6.  Simultaneous lesion and brain segmentation in multiple sclerosis using deep neural networks.

Authors:  Richard McKinley; Rik Wepfer; Fabian Aschwanden; Lorenz Grunder; Raphaela Muri; Christian Rummel; Rajeev Verma; Christian Weisstanner; Mauricio Reyes; Anke Salmen; Andrew Chan; Franca Wagner; Roland Wiest
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  Rim lesions are demonstrated in early relapsing-remitting multiple sclerosis using 3 T-based susceptibility-weighted imaging in a multi-institutional setting.

Authors:  Koy Chong Ng Kee Kwong; Daisy Mollison; Rozanna Meijboom; Elizabeth N York; Agniete Kampaite; Sarah-Jane Martin; David P J Hunt; Michael J Thrippleton; Siddharthan Chandran; Adam D Waldman
Journal:  Neuroradiology       Date:  2021-10-19       Impact factor: 2.804

Review 8.  Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide.

Authors:  Bart Van Wijmeersch; Hans-Peter Hartung; Patrick Vermersch; Maura Pugliatti; Carlo Pozzilli; Nikolaos Grigoriadis; Mona Alkhawajah; Laura Airas; Ralf Linker; Celia Oreja-Guevara
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

Review 9.  Predictive MRI Biomarkers in MS-A Critical Review.

Authors:  Vlad Eugen Tiu; Iulian Enache; Cristina Aura Panea; Cristina Tiu; Bogdan Ovidiu Popescu
Journal:  Medicina (Kaunas)       Date:  2022-03-03       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.